Alnylam presents positive results from illuminate-c phase 3 study of lumasiran in patients with advanced primary hyperoxaluria type 1

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today positive results from the 6-month primary analysis of the illuminate-c phase 3 open-label study of lumasiran, an rnai therapeutic targeting hydroxyacid oxidase 1 (hao1) – the gene encoding glycolate oxidase (go) – that is being investigated for the treatment of patients of all ages with advanced primary hyperoxaluria type 1 (ph1). the clinical data were present
ALNY Ratings Summary
ALNY Quant Ranking